CN108853007A - A kind of gel preparation and application thereof for treating functional uterine bleeding - Google Patents
A kind of gel preparation and application thereof for treating functional uterine bleeding Download PDFInfo
- Publication number
- CN108853007A CN108853007A CN201811103487.0A CN201811103487A CN108853007A CN 108853007 A CN108853007 A CN 108853007A CN 201811103487 A CN201811103487 A CN 201811103487A CN 108853007 A CN108853007 A CN 108853007A
- Authority
- CN
- China
- Prior art keywords
- weight
- gel preparation
- treatment
- aiweimopan
- uterine bleeding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Abstract
The invention belongs to field of medicaments, in particular to a kind of gel preparation and application thereof for treating functional uterine bleeding.The active constituent of the gel preparation be Aiweimopan or Aiweimopan and she can it is appropriate because composition, wherein Aiweimopan with she can it is appropriate because weight part ratio be：1 parts by weight of Aiweimopan, she can be appropriate because of 3~5 parts by weight.Gel preparation topical administration or Via vagina local administration of the invention have the function of shorten functional uterine bleeding bleeding time, Aiweimopan or she can it is appropriate because be used alone can play effect, effect further increases when being used in combination.
Description
Technical field
The invention belongs to field of medicaments, and in particular to a kind of gel preparation and application thereof for treating functional uterine bleeding.
Background technique
Functional uterine bleeding is to adjust the non-organic uterine hemorrhage disease caused extremely by hypothalamic-pituitary-ovarian axis
Become.This disease accounts for about the 10% of outpatients of gynecology.According to there is No-clay weak interbed that can be divided into two class of No-clay weak interbed type and ovulation type, the former is row
Obstacle occurs for ovum function, is mainly in puberty and climacteric；The latter belongs to luteal phase dysfunction, is mainly in Women of Childbearing Age, and 80%
The above patient is anovulatory dysfunctional uterine hemorrhage.According to disease stage, this disease can be divided into pubertal dysfunctional uterine bleeding,
Child-bearing period functional uterine bleeding, dysfunctional uterine bleeding during peri-menopausal period.Patients with clinical manifestations is mostly to prolong in hyper-menorrhea, menstrual period
Long and metrorrhagia, serious person can cause anemia, secondary infection, endometrial hyperplasia or gland cancer, or even need to cut
Except uterus.
Different treatment methods can be used according to patient age, fertility requirement etc. in treatment for functional uterine bleeding.
Wherein pubertal dysfunctional uterine bleeding is mainly focused on effectively stops blooding rapidly in hemorrhagic phase, then adjusts the menstrual cycle,
Ovulation function is established to prevent recurrence.Child-bearing period functional uterine bleeding needs effectively stop blooding rapidly in hemorrhagic phase, complete to stop
Being directed to after blood has fertility claimer that promoting ovulation drug can be suitably used.Climacteric Dysfunctional Uterine Bleeding with stop blooding, reduce blood volume,
Preventing Endometrial Diseases is principle.Patient's estrogen and progestogen level declines, but based on progestational hormone deficiency, clinically mainly
It is treated using Curettage.It can be seen that the hemostasis in hemorrhagic phase is primarily controlling for each age group functional uterine bleeding
Treat principle.
Modern medicine mainly uses estrogen, androgen, progestational hormone etc. to stop blooding functional uterine bleeding.Estrogen
Endometrial hyperplasia can be stimulated, the surface of a wound is repaired, but can cause more serious bleeding after being discontinued, and gastrointestinal reaction compares
Seriously.Progestational hormone is suitable for all types of bleedings, can promote endometrium synchronism secretionization, to achieve the purpose that hemostasis.Hero swashs
Element is used as complementary therapy, it is therefore an objective to which antiestrogenic reduces pelvic congestion and enhancing uterus Muscle tensility and reduces amount of bleeding, but cannot
Shorten bleeding time and completely hemostasis.Other drugs for being used for functional uterine bleeding include hemostatic, anti-fibrinolytic medicine, prostate
Plain synthetase inhibitors.Male contraceptive pill such as gossypol has been used for functional uterine bleeding early in the 1980s in China
Treatment.
In Traditional Chinese medical theory, functional uterine bleeding belongs to " metrorrhagia and metrostaxis " scope, needs according to different dialectical results
Discuss and control, therefore treatment method is complex.Existing document report shows that madder extract can go out dysfunctional uterine
Blood rat plays anastalsis, promotes the reparation of ovariectomized female rats endometrium and blood vessel hyperplasia, goes out to treat dysfunctional uterine
Blood.
But the drug that presently, can be used in functional uterine bleeding treatment is fewer.And it is estrogen, androgen, pregnant
The problems such as hormone medicine is mostly to be administered orally, and there are GI irritation effects, and there are withdrawal bleedings.
Summary of the invention
For the above-mentioned prior art, an object of the present invention is to provide a kind of gel system for treating functional uterine bleeding
Agent.
In order to achieve the above object, the technical solution adopted by the present invention is：
A kind of gel preparation for treating functional uterine bleeding, contains pharmaceutic adjuvant and Aiweimopan.
Preferably, it is described treatment functional uterine bleeding gel preparation also contain she can it is appropriate because.
It is further preferred that it is described treatment functional uterine bleeding gel preparation in Aiweimopan and Yi Ke it is appropriate because weight
Amount part, which is compared, is：1 parts by weight of Aiweimopan, she can be appropriate because of 3~5 parts by weight.
Preferably, it is described treatment functional uterine bleeding gel preparation in Aiweimopan and Yi Ke it is appropriate because weight part ratio
For：1 parts by weight of Aiweimopan, she can be appropriate because of 3 parts by weight.
Preferably, it is described treatment functional uterine bleeding gel preparation in Aiweimopan and Yi Ke it is appropriate because weight part ratio
For：1 parts by weight of Aiweimopan, she can be appropriate because of 4 parts by weight.
Preferably, it is described treatment functional uterine bleeding gel preparation in Aiweimopan and Yi Ke it is appropriate because weight part ratio
For：1 parts by weight of Aiweimopan, she can be appropriate because of 5 parts by weight.
Preferably, the gel preparation of the treatment functional uterine bleeding is external-use gel preparation, the treatment function
Property uterine hemorrhage the pharmaceutic adjuvant of gel preparation include card pool nurse 940, propylene glycol, glycerol, triethanolamine, azone and go
Ionized water；Card pool nurse 940, propylene glycol, glycerol, triethanolamine and laurel in the gel preparation of the treatment functional uterine bleeding
The weight part ratio of azone is：Card pool 940 3 parts by weight of nurse, 3 parts by weight of propylene glycol, 6 parts by weight of glycerol, 10 weight of triethanolamine
Part, 10 parts by weight of azone；The dosage of card pool nurse 940 is Ai Weimo in the gel preparation of the treatment functional uterine bleeding
7.5 times of Pan Chongliang.
In a preferred scheme, unit packaging preparation containing external-use gel be 10g, wherein containing Aiweimopan 20mg,
She can be appropriate because of 0~100mg, card pool 940 150 mg of nurse, 150 mg of propylene glycol, 300 mg of glycerol, triethanolamine 500mg, laurel
Azone 500mg, surplus are deionized water.Specifically preparation method is：（1）Recipe quantity card pool nurse -940 plus deionized water is taken to be configured to
4% concentrated solution is stood overnight, and is sufficiently swollen, and recipe quantity glycerol then is added, gel-type vehicle is made in triethanolamine；（2）Take prescription
Amount Aiweimopan, she can it is appropriate because, propylene glycol, azone be added gel-type vehicle in stir evenly, then be added surplus deionization
It stirs evenly；It dispenses to obtain the final product.Wherein she can be appropriate because of content optional then 0,60, tetra- 80,100mg gradients, when she can be appropriate because of content
When for 0mg, step（2）In be added without she can it is appropriate because.
Preferably, the gel preparation of the treatment functional uterine bleeding is vagina gel preparation, the treatment function
Can property uterine hemorrhage gel preparation pharmaceutic adjuvant include poloxamer188, PLURONICS F87, Tween 80, glycerol and go from
Sub- water；Poloxamer188 in the gel preparation of the treatment functional uterine bleeding, PLURONICS F87, Tween 80 and glycerol
Weight part ratio is：407 12 parts by weight of Luo Shamu, 5 parts by weight of PLURONICS F87,5 parts by weight of Tween 80,2 parts by weight of glycerol；
The dosage of Luo Shamu 407 is 60 times of Aiweimopan weight in the gel preparation of the treatment functional uterine bleeding.
In a preferred scheme, unit packaging gel preparation 10g containing vagina, wherein containing Aiweimopan 20mg,
She can be appropriate because of 0~100mg, 407 1200mg of Luo Shamu, 500 mg of PLURONICS F87,500 mg of Tween 80, glycerol 200
Mg, surplus are deionized water.Taken when preparation recipe quantity Aiweimopan, she can it is appropriate because, Tween 80, glycerol mixing, then at addition
Side amount Luo Shamu 407, PLURONICS F87 and deionized water, stir evenly, dispense to obtain the final product.Wherein she can be appropriate because content is optional then
0,60, tetra- 80,100mg gradients, when she can it is appropriate because content be 0mg when, be added without in preparation process she can it is appropriate because.
Another aspect of the present invention, the gel preparation for additionally providing above-mentioned treatment functional uterine bleeding are functional in preparation
Purposes in uterine hemorrhage therapeutic agent.
Aiweimopan described in technical solution of the present invention, English are entitled：Alvimopan；Technical solution of the present invention institute
State she can it is appropriate because, English it is entitled：Ectoine；Azone described in technical solution of the present invention, English are entitled
Laurocapram。
When specifically used, the gel preparation for the treatment of functional uterine bleeding of the invention by lower abdomen dermal application or
Vagina administration, drug become gel, slow release drug in skin and intravaginal.It is 60kg calculating, external application with human body weight
Or the dosage that is administered daily that vagina administration is recommended is calculated as 1 mg~2mg according to Aiweimopan.
The gel preparation for the treatment of functional uterine bleeding of the invention can shorten the uterine hemorrhage time, be used alone or with
The haemostatic effect that oral sex hormone, progestin combinations use is preferable.To those skilled in the art, dysfunctional uterine goes out
Blood needs to promote endometrial growth using sex hormone after completing hemostasis, or using Estrogen and progestin sequential therapy adjustment menstruation week
Phase, this was well-known to prevent bleeding again.Therefore, the gel preparation for the treatment of functional uterine bleeding of the invention is only used
In the short that the hemostasis of hemorrhagic phase is the bleeding phase.
Specific embodiment
Below with reference to embodiment, the present invention will be further explained.It should be understood that following embodiment is only used for solving
The present invention is released, rather than is limited the scope of the invention.
The external-use gel preparation of the treatment functional uterine bleeding of embodiment 1
Prescription：Aiweimopan 200mg, card pool 940 1500 mg of nurse, 1500 mg of propylene glycol, 3000 mg of glycerol, triethanolamine
5000mg, azone 5000mg, adding deionized water ad pond om is 100g.
Preparation method：（1）It takes recipe quantity card pool nurse -940 plus deionized water to be configured to 4% concentrated solution to stand overnight, sufficiently
Swelling,
Then recipe quantity glycerol is added, gel-type vehicle is made in triethanolamine；（2）Take recipe quantity Aiweimopan, propylene glycol, laurel nitrogen
Ketone is added in gel-type vehicle, and 800 revs/min are stirred 10 minutes, is then added 800 revs/min of surplus deionization and stirs 10 minutes；
It dispenses to obtain the final product.
The external-use gel preparation of the treatment functional uterine bleeding of embodiment 2
Prescription：Aiweimopan 200mg, she can it is appropriate because 600mg, card pool 940 1500 mg of nurse, 1500 mg of propylene glycol, glycerol 3000
Mg, triethanolamine 5000mg, azone 5000mg, adding deionized water ad pond om is 100g.
Preparation method：（1）It takes recipe quantity card pool nurse -940 plus deionized water to be configured to 4% concentrated solution to stand overnight, sufficiently
Then recipe quantity glycerol is added in swelling, gel-type vehicle is made in triethanolamine；（2）Take recipe quantity Aiweimopan, she can it is appropriate because, third
Glycol, azone are added in gel-type vehicle, and 800 revs/min are stirred 10 minutes, are then added 800 revs/min of surplus deionization
Stirring 10 minutes；It dispenses to obtain the final product.
The external-use gel preparation of the treatment functional uterine bleeding of embodiment 3
Prescription：Aiweimopan 200mg, she can it is appropriate because 800mg, card pool 940 1500 mg of nurse, 1500 mg of propylene glycol, glycerol 3000
Mg, triethanolamine 5000mg, azone 5000mg, adding deionized water ad pond om is 100g.
Preparation method：（1）It takes recipe quantity card pool nurse -940 plus deionized water to be configured to 4% concentrated solution to stand overnight, sufficiently
Swelling,
Then recipe quantity glycerol is added, gel-type vehicle is made in triethanolamine；（2）Take recipe quantity Aiweimopan, she can it is appropriate because, the third two
Alcohol, azone are added in gel-type vehicle, and 800 revs/min are stirred 10 minutes, are then added 800 revs/min of surplus deionization and stir
It mixes 10 minutes；It dispenses to obtain the final product.
The external-use gel preparation of the treatment functional uterine bleeding of embodiment 4
Prescription：Aiweimopan 200mg, she can it is appropriate because 1000mg, card pool 940 1500 mg of nurse, 1500 mg of propylene glycol, glycerol
3000 mg, triethanolamine 5000mg, azone 5000mg, adding deionized water ad pond om is 100g.
Preparation method：（1）It takes recipe quantity card pool nurse -940 plus deionized water to be configured to 4% concentrated solution to stand overnight, sufficiently
Swelling,
Then recipe quantity glycerol is added, gel-type vehicle is made in triethanolamine；（2）Take recipe quantity Aiweimopan, she can it is appropriate because, the third two
Alcohol, azone are added in gel-type vehicle, and 800 revs/min are stirred 10 minutes, are then added 800 revs/min of surplus deionization and stir
It mixes 10 minutes；It dispenses to obtain the final product.
The vagina gel preparation of the treatment functional uterine bleeding of embodiment 5
Prescription：407 12000mg of Aiweimopan 200mg, Luo Shamu, 5000 mg of PLURONICS F87,5000 mg of Tween 80,
2000 mg of glycerol, adding deionized water ad pond om is 100g.
Preparation method：Recipe quantity Aiweimopan, Tween 80, glycerol mixing are taken, recipe quantity Luo Shamu 407, pool is then added
Luo Shamu 188 and deionized water, are stirred 10 minutes, are dispensed by 800 revs/min to obtain the final product.
The vagina gel preparation of the treatment functional uterine bleeding of embodiment 6
Prescription：Aiweimopan 200mg, she can it is appropriate because of 407 12000mg of 600mg, Luo Shamu, 5000 mg of PLURONICS F87, spit
80 5000 mg of temperature, 2000 mg of glycerol, adding deionized water ad pond om is 100g.
Preparation method：Take recipe quantity Aiweimopan, she can be appropriate because of, Tween 80, glycerol mixing, it is husky that recipe quantity Lip river is then added
Nurse 407, PLURONICS F87 and deionized water, are stirred 10 minutes, are dispensed by 800 revs/min to obtain the final product.
The vagina gel preparation of the treatment functional uterine bleeding of embodiment 7
Prescription：Aiweimopan 200mg, she can it is appropriate because of 407 12000mg of 800mg, Luo Shamu, 5000 mg of PLURONICS F87, spit
80 5000 mg of temperature, 2000 mg of glycerol, adding deionized water ad pond om is 100g.
Preparation method：Take recipe quantity Aiweimopan, she can be appropriate because of, Tween 80, glycerol mixing, it is husky that recipe quantity Lip river is then added
Nurse 407, PLURONICS F87 and deionized water, are stirred 10 minutes, are dispensed by 800 revs/min to obtain the final product.
The vagina gel preparation of the treatment functional uterine bleeding of embodiment 8
Prescription：Aiweimopan 200mg, she can it is appropriate because 407 12000mg of 1000mg, Luo Shamu, 5000 mg of PLURONICS F87,
5000 mg of Tween 80,2000 mg of glycerol, adding deionized water ad pond om is 100g.
Preparation method：Take recipe quantity Aiweimopan, she can be appropriate because of, Tween 80, glycerol mixing, it is husky that recipe quantity Lip river is then added
Nurse 407, PLURONICS F87 and deionized water, are stirred 10 minutes, are dispensed by 800 revs/min to obtain the final product.
Embodiment 9 treats the gel preparation of functional uterine bleeding to the rat functional uterine bleeding model bleeding time
It influences
SPF grades of health Sprague Dawley rats, male and female dual-purpose, weight 230 g~250 g.Male and female divide cage adaptive feeding 7
Day.After adaptive feeding, by rat according to male female 2 when daily afternoon 19:1 ratio carries out mating raising, daily
When the morning 6~8 when check vaginal plug.
To find vaginal plug as female rats gestation the 1st day, pregnant rat is randomly divided into 5 groups, every group 6.Each group is pregnant
Rat of being pregnent gavages 8.3 mg of mifepristone/kg weight when the pregnant 7th day morning 9, and whens afternoon 17 gavages Misoprostol
0.1 mg/kg weight establishes rat functional uterine bleeding model.Cotton balls is then filled in into rat vagina, to observe bleeding
Situation.There is the start time that visible blood is recorded as uterine hemorrhage using first observed to cotton balls, every 1 cotton balls of replacement in 12 hours
1 bleeding situation is observed, until cotton balls is without visible blood.Every rat vagina bleeding time（Hour）=first observed to cotton balls without
It can be seen that the time of blood（Hour）-6.If time of the first observed to cotton balls without visible blood is after uterine hemorrhage records start time
48h, then the practical uterine hemorrhage time is recorded as 42h.
Each group rat gavages next day i.e. pregnant 8th day progress back preserved skin, preserved skin positional distance respectively at Misoprostol
Tail base is 2cm, and shaving sterilizes, and preserved skin area is at least 1x1cm2, carry out smearing administration.
1st group of rat is model group, smears physiological saline in shaving region.2nd to 4 group rat is experimental group, in shaving
Gel prepared by embodiment 1,2,4 is smeared in region, and every rat is smeared 1 time daily, and every rat uses 0.01ml gel every time.
5th group of rat is control group, and smearing her in shaving region can be appropriate because of aqueous solution（Concentration is 0.5mg/ml）, every rat makes every time
With 0.2ml solution.Each group rat is to be administered daily 1 time, and successive administration 28 days.24 hours after the last administration, it is big to put to death each group
Mouse, coring, liver, kidney, uterus routinely prepare paraffin section, HE dyeing observation each group rat organ pathological change situation.
The observation of rat bleeding time and pathological observation are all made of blind observation：
I.e. bleeding time observer and pathological observation personnel are grouped experimental animal and are administered in single blind state, in order to avoid experiment
Personnel's subjective tendency impacts experimental result.
After the bleeding time statistics of every rat, unite to the mean value and standard deviation in each group rat bleeding time
Then meter is compared the bleeding time of each group rat using one-way analysis of variance and post hoc inspection.Experimental result
It see the table below：
Each group rat bleeding time statistics（n=6）
* the p compared with the 1st group is indicated<0.01；# indicates the p compared with the 2nd group<0.05, ## indicates the p compared with the 2nd group<0.01.
As seen from the above table, the 5th group i.e. she can it is appropriate because be administered alone group bleeding time be considerably shorter than the 1st group i.e. model group
（p<0.01）, but considerably longer than the 2nd group of i.e. Aiweimopan is administered alone group（p<0.01）, illustrate that she can be appropriate because having the function of to shorten
The effect in temper palace bleeding time, but effect is lower than Aiweimopan.
2nd group be administered alone to the 4th group i.e. Aiweimopan or Aiweimopan and she can the appropriate bleeding because of administering drug combinations group when
Between be considerably shorter than model group（p<0.01）, and the 3rd, the 4th group（Aiweimopan can be appropriate because of administering drug combinations group with her）Bleeding time
Considerably shorter than the 2nd group (Aiweimopan is administered alone group).Illustrate that Aiweimopan exclusive use can shorten functional uterine bleeding
It bleeding time, can be appropriate because the effect being used in combination is more excellent with her.
Each group rat pathology section examination has no significant pathological change.Illustrate Aiweimopan and she can be appropriate because topical administration exists
Under the dosage and administration duration, good security.
Claims (9)
1. a kind of gel preparation for treating functional uterine bleeding, contains pharmaceutic adjuvant and Aiweimopan.
2. the gel preparation for the treatment of functional uterine bleeding according to claim 1, which is characterized in that the treatment function
The gel preparation of property uterine hemorrhage also contain she can it is appropriate because.
3. the gel preparation for the treatment of functional uterine bleeding according to claim 2, which is characterized in that the treatment function
In the gel preparation of property uterine hemorrhage Aiweimopan and Yi Ke it is appropriate because weight part ratio be：1 parts by weight of Aiweimopan, she can it is appropriate because
3~5 parts by weight.
4. the gel preparation for the treatment of functional uterine bleeding according to claim 3, which is characterized in that the treatment function
In the gel preparation of property uterine hemorrhage Aiweimopan and Yi Ke it is appropriate because weight part ratio be：1 parts by weight of Aiweimopan, she can it is appropriate because
3 parts by weight.
5. the gel preparation for the treatment of functional uterine bleeding according to claim 3, which is characterized in that the treatment function
In the gel preparation of property uterine hemorrhage Aiweimopan and Yi Ke it is appropriate because weight part ratio be：1 parts by weight of Aiweimopan, she can it is appropriate because
4 parts by weight.
6. the gel preparation for the treatment of functional uterine bleeding according to claim 3, which is characterized in that the treatment function
In the gel preparation of property uterine hemorrhage Aiweimopan and Yi Ke it is appropriate because weight part ratio be：1 parts by weight of Aiweimopan, she can it is appropriate because
5 parts by weight.
7. according to claim 1 to the gel preparation for the treatment of functional uterine bleeding described in 6, which is characterized in that the treatment
The pharmaceutic adjuvant of the gel preparation of functional uterine bleeding includes card pool nurse 940, propylene glycol, glycerol, triethanolamine, azone
And deionized water；It is described treatment functional uterine bleeding gel preparation in card pool nurse 940, propylene glycol, glycerol, triethanolamine and
The weight part ratio of azone is：Card pool 940 3 parts by weight of nurse, 3 parts by weight of propylene glycol, 6 parts by weight of glycerol, 10 weight of triethanolamine
Measure part, 10 parts by weight of azone；The dosage of card pool nurse 940 is love dimension in the gel preparation of the treatment functional uterine bleeding
Not 7.5 times of Pan Chongliang.
8. according to claim 1 to the gel preparation for the treatment of functional uterine bleeding described in 6, which is characterized in that the treatment
The pharmaceutic adjuvant of the gel preparation of functional uterine bleeding includes poloxamer188, PLURONICS F87, Tween 80, glycerol and goes
Ionized water；Poloxamer188, PLURONICS F87, Tween 80 and glycerol in the gel preparation of the treatment functional uterine bleeding
Weight part ratio be：407 12 parts by weight of Luo Shamu, 5 parts by weight of PLURONICS F87,5 parts by weight of Tween 80,2 weight of glycerol
Part；The dosage of Luo Shamu 407 is 60 times of Aiweimopan weight in the gel preparation of the treatment functional uterine bleeding.
9. the gel preparation for the treatment of functional uterine bleeding described in claim 1 to 8 is in preparation functional uterine bleeding treatment
Purposes in drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811103487.0A CN108853007B (en) | 2018-09-20 | 2018-09-20 | A kind of gel preparation and application thereof for treating functional uterine bleeding |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811103487.0A CN108853007B (en) | 2018-09-20 | 2018-09-20 | A kind of gel preparation and application thereof for treating functional uterine bleeding |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108853007A true CN108853007A (en) | 2018-11-23 |
| CN108853007B CN108853007B (en) | 2019-05-28 |
Family
ID=64324578
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811103487.0A Expired - Fee Related CN108853007B (en) | 2018-09-20 | 2018-09-20 | A kind of gel preparation and application thereof for treating functional uterine bleeding |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108853007B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103948593A (en) * | 2014-05-21 | 2014-07-30 | 福建省微生物研究所 | Alvimopan medicine composition and preparation method thereof |
-
2018
- 2018-09-20 CN CN201811103487.0A patent/CN108853007B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103948593A (en) * | 2014-05-21 | 2014-07-30 | 福建省微生物研究所 | Alvimopan medicine composition and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| 海关总署关税征管司: "《医药商品归类手册 原料药、制剂分册》", 31 July 2014, 中国商务出版社 * |
| 郝天羽: "《临床生殖医学与进展》", 31 December 2011, 天津科学技术出版社 * |
| 阴永辉: "《中医临床实习手册 内分泌科》", 31 October 2013, 中国医药科技出版社 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108853007B (en) | 2019-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kupperman et al. | Contemporary therapy of the menopausal syndrome | |
| JP6124411B2 (en) | Monolithic intravaginal rings containing progesterone and methods for their production and use | |
| KR101288265B1 (en) | Methods for the treatment of endometriosis | |
| TW200831107A (en) | Methods of hormonal treatment utilizing ascending-dose extended cycle regimens | |
| HU221583B (en) | Use of a cross-linked polycarboxylic polymer and progesterone for the manufacture of a medicament suitable for vaginal delivery | |
| PT1539184E (en) | Estrogen replacement regimen | |
| EA028780B1 (en) | Use of estetrol as emergency contraceptive | |
| Buggio et al. | “Per vaginam” topical use of hormonal drugs in women with symptomatic deep endometriosis: a narrative literature review | |
| Kohama et al. | Effect of French maritime pine bark extract on endometriosis as compared with leuprorelin acetate | |
| JP6818047B2 (en) | A composition for preventing, ameliorating or treating female menopausal syndrome containing loganin or a derivative thereof as an active ingredient. | |
| JPH04273822A (en) | Therapeutic drug for endometritis | |
| CN108853007B (en) | A kind of gel preparation and application thereof for treating functional uterine bleeding | |
| Murray | Natural progesterone: what role in women’s health care | |
| JP2002527380A (en) | Subcutaneous medroxyprogesterone acetate for treatment of menopause and endometriosis | |
| JP2010100547A (en) | Agent for reducing or preventing side effect of hormone therapy and agent for suppressing or preventing recurrence of dysmenorrhea after hormone therapy | |
| CN101152345B (en) | Traditional Chinese medicine preparation for treating female acyesis caused by ovulation obstacle | |
| CN112353933B (en) | Medicine for preventing and/or treating hysteromyoma and preparation method thereof | |
| US9339458B2 (en) | Use of vaginal insulin sensitizing agents | |
| Castelo-Branco et al. | Compounds for the treatment of atropic vaginitis | |
| Maia et al. | Short Term Effects of the Vaginal Administration of Gestrinone and Miodesi on Endometriosis Pain | |
| RU2471485C1 (en) | Method of treating benign hyperplastic processes of female reproductive system | |
| Lemay | Ovarian Suppression by GnRH Agonists | |
| MXPA06014162A (en) | Use of 7-t-butoxyiminomethylcamptothecin for the prepartion of a medicament for the treatment of uterine neoplasms. | |
| CN105168632A (en) | Traditional Chinese medicinal plastics for promoting healing of wound of cesarean section and preparation method thereof | |
| TEJASWI | A RANDOMISED CONTROL TRIAL TO KNOW THE SAFETY AND EFFICACY OF ORAL MIFEPRISTONE IN PREINDUCTION OF LABOUR IN POST DATED PREGNANCY” |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20190528 Termination date: 20210920 |